There are currently 1244 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121
Recruiting
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Sarah Cannon Cancer Network, Nashville, Tennessee
Conditions: Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Register for Updates
Post-market Study of the Biodesign Hernia Graft
NCT04294446
Recruiting
The purpose of this study is to collect data on the performance of the Biodesign® Hernia Graft when used to reinforce soft tissues during ventral hernia repair.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Ventral Hernia
Register for Updates
International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
NCT04496687
Recruiting
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Spontaneous Coronary Artery Dissection
Register for Updates
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
NCT05805709
Recruiting
The COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal intervention to usual care on hospital-free days through 90 days of study follow up. The primary study hypothesis is that patients randomized to the intervention will have increased odds of more hospital-free days through 90 days (primary clinical) compared to those randomized to usual care. Key secondary hypotheses will investigate the impact of the intervention on rates of major adverse kidney events, rate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Nashville VA Medical Center, Nashville, Tennessee +1 locations
Conditions: Acute Kidney Injury
Register for Updates
2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
NCT04941599
Recruiting
The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks.
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
12/11/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Familial Hypercholesterolemia
Register for Updates
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT05388708
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Register for Updates
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933
Recruiting
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
12/09/2024
Locations: Vanderbilt University School of Medicine, Nashville, Tennessee
Conditions: Colorectal Adenocarcinoma, Ewing Sarcoma
Register for Updates
Gravity Versus Vacuum Based Indwelling Tunneled Pleural Drainage System
NCT03831386
Recruiting
Malignant pleural effusion remains a debilitating complication of end stage cancer, which can be greatly improved by the introduction of the indwelling tunneled pleural catheter (IPC). However, there is no standard of care regarding drainage and limited data on the utility of different drainage techniques. In addition, many patients develop discomfort and chest pain during drainage. The investigators propose to evaluate gravity drainage and suction drainage on quality of life measures and outcom... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Pleural Effusion
Register for Updates
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
NCT05901545
Recruiting
This phase I trial tests the safety and effectiveness of indium In 111 panitumumab (111In-panitumumab) for identifying the first lymph nodes to which cancer has spread from the primary tumor (sentinel lymph nodes) in patients with head and neck squamous cell carcinoma (HNSCC) undergoing surgery. The most important factor for survival for many cancer types is the presence of cancer that has spread to the lymph nodes (metastasis). Lymph node metastases in patients with head and neck cancer reduce... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
12/09/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Register for Updates
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients with Head and Neck Cancer
NCT05945875
Recruiting
This phase I trial evaluates the safety and effectiveness of using two imaging techniques, indium In 111 panitumumab (111In-panitumumab) with single photon emission computed tomography (SPECT)/computed tomography (CT) and panitumumab-IRDye800 fluorescence imaging during surgery (intraoperative), to detect disease in patients with head and neck cancer. 111In-panitumumab is an imaging agent made of a monoclonal antibody that has been labeled with a radioactive molecule called indium In 111. The ag... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
12/09/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Register for Updates
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
NCT06075810
Recruiting
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/09/2024
Locations: Sarah Cannon Research Institute/SCRI, Nashville, Tennessee
Conditions: Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
Register for Updates
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
NCT06654895
Recruiting
The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic shock.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
12/09/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Sepsis, Septic Shock
Register for Updates